TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES TYPE-1 (TIMP-1) AS A POSTOPERATIVE MARKER FOR MINIMAL RESIDUAL DISEASE OR RECURRENT DISEASE IN PATIENTS WITH A PRIOR HISTORY OF CANCER

摘要

The present invention describes a method for determining whether an individual is suffering from minimal residual diseases or recurrent cancer during treatment and/or after being treated for the primary cancer by determining a parameter representing the post-operative TIMP-1 concentration in body fluid samples from the individual. In addition, the invention describes the additive effect of combined post-operative measurements of plasma TIMP-1 and serum CEA.